花旗-恒瑞医药(600276.SS):中国医疗健康调研新动向:业务拓展动能延续,创新药销售指引维持不变-Jiangsu Hengrui Pharmaceuticals(600276.SS):What’s new from China Healthcare Tour:Continued BD momentum;innovative dr-20260615【11页】

发表回复

后才能评论